Septal ablation, a valid alternative for obstructive hypertrophic cardiomyopathy

Original title: Survival of Patients ≤50 Years Alter Alcohol Septal Ablation for Hypertrofic Obstructive Cardiomyopathy. Reference: Josef Veselka, et al. Canadian Journal of Cardiology 2014,30:634-638

Treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM) is the surgical septal myomectomy nevertheless, currently arose several studies reporting a favourable evolution and comparable to surgery with septal ablation (AS). 75 patients under 50 years of age with HCM, 85 procedures were performed. The primary endpoint was all-cause mortality, and the secondary was all-cause mortality or defibrillator implant.

Average age of the population was 42 ± 7 years all symptomatic with a gradient of 73 ± 38 mmHg and the basal septum thickness of 23 ± 6 mm. Post procedure, 8% had complete AV block and 2.7% transient AV block with a need for permanent pacemaker of 6.7%. Follow-up was performed in all patients at 5.1 years showing significant improvement in functional class associated with a fall in the gradient outflow tract and decreased thickness in the basal septum.

Four patients died during follow-up (1 to 30 days by sudden death, 1 by stroke, 1 from gastrointestinal bleeding and 1 for cancer), only two were attributed to the underlying disease. Survival rates at 1, 3 and 5 years were 97%, 94%, and 94%, respectively, not being able to identify predictors of mortality in the multivariate analysis. The risk of death or need for a defibrillator was not associated with post septal ablation gradient.

Conclusion: 

This study in patients with obstructive hypertrophic cardiomyopathy (HCM) under 50 years who received septal ablation suggests a low risk of death from any cause or defibrillator implant in the long-term monitoring. 

Editorial comment 

Myomectomy remains the best strategy for those patients who are operated; however, this study showed a favourable evolution and comparable to surgery in young people; septal ablation is a less aggressive behaviour. More research is needed. 

Courtesy Dr. Carlos Fava
Interventional cardiologist
Favaloro Foundation
Argentina

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...